Cyber Risk Experts in Switzerland
Cybersecurity Testing: A Regulatory Expectation, Not an Option
Medical devices today are no longer isolated systems. They operate across hospital networks, cloud platforms, mobile applications, and remote monitoring environments. This connectivity introduces cyber risks that can directly affect patient safety, device availability, and clinical decision-making.
Recognizing this reality, the FDA requires manufacturers to demonstrate robust cybersecurity controls as part of the 510(k) premarket submission. For medical device companies in Switzerland, security testing—particularly Vulnerability Assessment and Penetration Testing (VA/PT)—is essential to prove cybersecurity effectiveness. Cyberintelsys supports Swiss manufacturers by delivering regulatory-focused security testing aligned with FDA guidance, CREST best practices, and IEC standards.
FDA 510(k) Cybersecurity: What Regulators Expect to See
FDA cybersecurity reviews focus on whether manufacturers can:
Identify cybersecurity threats and vulnerabilities
Assess risks based on patient safety and essential performance
Implement effective security controls
Validate controls through structured testing
Maintain cybersecurity throughout the product lifecycle
Security testing and VA/PT provide objective evidence that these expectations are met.
Security Testing for Medical Devices: A Broader View
Medical device security testing extends beyond traditional IT testing. It evaluates how cyber threats interact with clinical workflows, device functions, and safety mechanisms.
Typical Assessment Scope
Embedded software and firmware
Device operating systems and communication protocols
APIs and cloud back-end systems
Mobile and web-based clinical applications
Third-party and open-source components
Cyberintelsys applies a medical-device-specific testing approach, ensuring results are meaningful for FDA reviewers.
Vulnerability Assessment: Building a Risk Visibility Baseline
Vulnerability assessment identifies known and emerging security weaknesses across the device ecosystem.
Why It Matters for FDA 510(k)
Supports FDA-required cybersecurity risk analysis
Helps prioritize risks based on clinical impact
Reduces surprises late in regulatory review
Strengthens secure-by-design decision-making
Cyberintelsys combines automated scanning with manual analysis and IEC-aligned risk classification to ensure accuracy and relevance.
Penetration Testing: Proving Real-World Cyber Resilience
While vulnerability assessments identify weaknesses, penetration testing demonstrates exploitability—a key FDA expectation.
What Penetration Testing Demonstrates
Whether attackers can bypass authentication
Potential manipulation of therapy or diagnostics
Unauthorized access to sensitive data
Availability risks through denial-of-service attacks
CREST-Aligned Penetration Testing
Cyberintelsys follows CREST-aligned methodologies, ensuring penetration testing is:
Ethical and controlled
Conducted by skilled, certified professionals
Focused on patient safety impact
Supported by clear remediation guidance
CREST alignment enhances testing credibility and regulatory confidence.
Mapping VA/PT Findings to FDA Documentation
A major challenge for manufacturers is converting technical findings into FDA-ready cybersecurity evidence.
Cyberintelsys ensures VA/PT results are mapped to:
Cybersecurity risk management files
Threat modeling and misuse case documentation
Verification and validation records
Residual risk justification
This structured mapping reduces FDA requests for additional information and accelerates approval timelines.
Alignment with IEC and Global Medical Device Standards
FDA cybersecurity expectations align closely with international standards. Security testing programs should support compliance with:
IEC 81001-5-1 – Cybersecurity risk management for health software
IEC 62304 – Software lifecycle processes
ISO 14971 – Risk management and patient safety
Secure-by-design and defense-in-depth principles
Cyberintelsys helps Swiss manufacturers harmonize FDA and IEC requirements within a single testing and documentation framework.
Risk-Based Testing Centered on Patient Safety
FDA reviewers prioritize risks that could cause patient harm or loss of essential performance.
Cyberintelsys evaluates each finding based on:
Clinical usage scenarios
Severity of safety impact
Likelihood of exploitation
Effectiveness of existing controls
This ensures cybersecurity decisions align with regulatory expectations—not just technical severity scores.
Post-Market Security Testing and Lifecycle Compliance
FDA 510(k) compliance continues after market clearance. Manufacturers must demonstrate ongoing cybersecurity vigilance.
Security testing supports post-market compliance by:
Validating updates and patches
Supporting coordinated vulnerability disclosure (CVD)
Identifying new risks from software changes
Strengthening incident response readiness
Cyberintelsys helps establish repeatable testing processes across the device lifecycle.
Why Swiss Manufacturers Trust Cyberintelsys
Cyberintelsys brings together cybersecurity expertise, regulatory insight, and medical device knowledge.
Key Differentiators
FDA 510(k)–focused VA/PT methodology
CREST-aligned penetration testing practices
IEC-based risk management expertise
Patient-safety-driven evaluation
Regulatory-ready reporting
This combination enables Swiss manufacturers to meet FDA expectations with confidence.
Conclusion: Strengthening FDA 510(k) Submissions Through Security Testing
Medical device security testing and VA/PT are essential for FDA 510(k) compliance. For manufacturers in Switzerland, these activities provide critical evidence of cybersecurity maturity, reduce regulatory risk, and protect patient safety.
By partnering with Cyberintelsys and adopting CREST-aligned testing methodologies supported by IEC standards, manufacturers can deliver secure, compliant medical devices and accelerate access to the U.S. market with confidence.
